Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia

James Scurry, Máire A Duggan

Abstract

The separation of mesothelial hyperplasia from early malignant mesothelioma remains one of the most difficult problems in histopathology. Inconclusive cases are termed “atypical mesothelial hyperplasia” and treated expectantly. A 49 year old male pipeline engineer was diagnosed as having atypical mesothelial hyperplasia in appendiceal serosa by the US–Canadian Mesothelioma Panel. Eight years later, he developed overtly malignant peritoneal and pleural mesothelioma. In hindsight, histological similarities between the diffuse malignant mesothelioma and the atypical mesothelial proliferation suggested malignancy from the outset. The most important of these features were the degree of mesothelial proliferation, micronodularity, architectural complexity, superficial invasion, uniform mild cytological atypia, and the absence of a clinical cause for a benign mesothelial proliferation. Ancillary investigations including immunohistochemistry were of no benefit in determining whether the atypical mesothelial hyperplasia was benign or malignant. Careful histological examination remains the mainstay of the diagnosis of early mesothelioma.

Keywords: atypical hyperplasia; mesothelium; malignant tumour; peritoneum

One of the most difficult areas in histopathology is the separation of early well differentiated malignant mesothelioma from benign mesothelial hyperplasia. The term “atypical mesothelial hyperplasia” has been introduced for cases where the diagnosis is uncertain. In these cases, the proliferating mesothelium shows some but not all the histological or cytological features of well differentiated mesotheliomas. This term encompasses benign mesothelial hyperplasias, premalignant mesothelial proliferations, and early well differentiated malignant mesotheliomas. The conventional wisdom is to observe patients with atypical mesothelial hyperplasia. Overt malignancy usually becomes manifest within months in cases where atypical mesothelial hyperplasia was in fact early mesothelioma. The justification for this approach is that surgery and adjuvant treatment in malignant mesothelioma have only a marginal effect on survival. To avoid morbidity to patients who in fact have reactive mesothelial hyperplasia, it is better to wait and see in doubtful cases. However, this approach is not ideal, as until premalignant and early diffuse malignant mesothelioma can be diagnosed reliably, it will be impossible to mount effective treatment trials for early disease. We present a case of atypical mesothelial hyperplasia found on the appendix in a 49 year old man who developed a diffuse malignant mesothelioma eight years later.

Case report

In 1989, a 49 year old male pipeline engineer, who had been working in fertiliser and gas processing plants on three continents since 1981, presented with right lower quadrant pain. A presumptive diagnosis of appendicitis was made. At laparotomy, the appendix and mesoappendix appeared thickened and were removed, but no other abnormality was noted. In 1994, he had two pulmonary emboli. At that stage, computed tomography of the abdomen showed thickened omentum and a small amount of free intraperitoneal fluid, but an ultrasound guided fine needle abdominal aspirate was negative for carcinoma. Extensive clinical, radiological, and biochemical investigation did not identify malignancy in any organ.

In late 1996, repeat computed tomography showed progressive thickening of the omentum, ascites, bilateral small pleural effusions, nodularity of the right greater pulmonary fissure, and mesenteric lymph node enlargement. In 1997, a right thoracocentesis for increasing pleural effusion revealed malignant cells on cytology. He underwent exploratory laparotomy. Ascites was confirmed, the peritoneal surface was diffusely thickened with small nodules of tumour, the omentum was infiltrated, and there were larger deposits of tumour in the right subphrenic space and on the spleen. Omental and mesenteric node biopsies were performed.

Pathology

External examination of the appendix (1989) showed pale thickening of the serosa and meso-appendix, but no tumour nodules were seen. Cut sections were normal. Histological examination showed no evidence of current or remote inflammation of the appendix. There was mild diffuse peritoneal fibrosis with scattered nests and small nodules of epithelioid cells up to 1.0 mm in diameter on and beneath the surface (fig 1). Most of the nests were solid, but there was a tendency for intercellular vacuoles and separation of the cells, so that rudimentary papillae were formed. The nests beneath the surface either communicated directly with fat, or were enveloped in a desmoplastic stroma. The cells had a strong
There are, however, subtle differences in this later biopsy of slightly more complex architecture, cytological atypia, and mitosis which make it more readily recognizable as malignant. The tumour cells were similar to those seen in the serosa of the appendix (fig 2), but showed a slightly higher degree of atypia. The mesenteric lymph node showed hyperplastic changes.

Mesothelial differentiation in the appendiceal and omental cellular proliferations was confirmed by the findings of alcian blue positive, hyaluronidase sensitive extracellular mucin, cytoplasmic border epithelial membrane antigen and intracytoplasmic cytokeratin immunostaining, and typical electron microscopic features including numerous long microvilli and extracellular spaces. Immunohistochemistry for p53 and Ki67 in both specimens was completely negative. Benign reactive mesothelium from a hernial sac of another patient used as a control showed occasional variably strong nuclear p53 reactivity in 5% of cells and Ki67 reactivity in 10% of cells. Flow cytometry performed on the omental tumour showed a purely normal DNA content, with 100% of the cells diploid and the DNA index 1.00, with 6% of cells in G2 phase and 2.8% in S phase.

A final diagnosis of diffuse malignant mesothelioma, epithelioid type, involving the peritoneum and pleura was made. An asbestos fibre count on tumour tissue was not performed.

Discussion

The confinement to serous cavities, histological features of a solid and tubopapillary epithelioid tumour, cytological features of cells with eosinophilic cytoplasm and central nuclei, hyaluronidase sensitive extracellular mucin, cytoplasmic keratin, cytoplasmic border epithelial membrane antigen, and electron microscopic features of the brush-like long microvilli all led to a diagnosis of diffuse epithelioid malignant mesothelioma in 1997. This was supported by the absence of any clinical or laboratory features to suggest an extraperitoneal primary site of malignancy.

The histological similarities between the tumour and the earlier serosal proliferation on the appendix from 1989 suggest that the tumour developed from this serosal proliferation. Originally, the serosal changes were diagnosed as “atypical mesothelial hyperplasia” by the US–Canadian Mesothelioma Panel. Although all panel members favoured a benign prognosis, the chairman (Dr E McCaughey) cautioned that he had not previously seen such a degree of proliferation in a benign case. In hindsight, the similarity with the diffuse malignant mesothelioma, degree of proliferation, stromal invasion, architectural complexity, uniformly mild cytological atypia, and absence of any potential cause of mesothelial hyperplasia all suggest early malignancy.

Sixty-five per cent of malignant mesotheliomas are diploid as in this case, so if this investigation had been performed on the appendiceal mesothelial proliferation, it would not have been helpful.2 p53 Immunostaining has been...
used to distinguish benign mesothelial proliferations from malignant mesothelioma, but was only present in 63 of 143 mesotheliomas (44%) when four studies are combined. Our results of negative atypical mesothelial hyperplasia and mesothelioma, but focal positivity in 5% of reactive mesothelial cells in a negative control urge caution in interpreting p53 immunostaining in mesothelial proliferations. Wild-type p53 may be stained by the commonly used antibodies.

A summary of the diagnostic features distinguishing mesothelial hyperplasia from early mesothelioma is given in table 1. Careful histological examination remains the key to diagnosis.

Eighty to ninety per cent of mesotheliomas in the United Kingdom appear to be related to previous asbestos exposure. Our patient had a 16 year history of potential occupational asbestos exposure by the time a definitive diagnosis of malignant mesothelioma was made in 1997. Ninety nine per cent of 1690 patients with mesotheliomas had a latent period of at least 15 years, and in 96% it was 20 years. The original mesothelial proliferation occurred after only eight years of potential exposure to asbestos, and supports the concept that the atypical mesothelial hyperplasia was malignant at the time of the appendectomy.

<table>
<thead>
<tr>
<th>Table 1 Summary of differentiating features between mesothelial hyperplasia and diffuse malignant mesothelioma (from references 1–10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
</tr>
<tr>
<td><strong>Gross</strong></td>
</tr>
<tr>
<td><strong>Histology</strong></td>
</tr>
<tr>
<td><strong>Cytology</strong></td>
</tr>
<tr>
<td><strong>Immunoperoxidase</strong></td>
</tr>
<tr>
<td><strong>Ploidy</strong></td>
</tr>
<tr>
<td><strong>Cytogenetics</strong></td>
</tr>
</tbody>
</table>

Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

J Scurry and M A Duggan

*J Clin Pathol* 1999 52: 535-537
doi: 10.1136/jcp.52.7.535

Updated information and services can be found at:
[http://jcp.bmj.com/content/52/7/535](http://jcp.bmj.com/content/52/7/535)

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)